Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Biemond

Showing results (201-210 of 209) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 209 results.
Blood Advances|October 31, 2025
Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Asparaginase-Treated ALLDaniela R Anderson, Radhika Gangaraju, Wafik G Sedhom, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2023
Clinical Impact of Polymerase Chain Reaction-Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter StudySammy Huygens, Albert Dunbar, Jochem B Buil, et al.
Vox Sanguinis|November 24, 2025
Multinational transfusion practices and outcomes in haematology patients admitted to the intensive care unitCaroline M Schaap, Laurens A Oomen, Senta Jorinde Raasveld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A studyMonique Terwijn, Wim L J van Putten, Angèle Kelder, et al.
Blood Advances|December 9, 2021
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trialAnita W Rijneveld, Bronno van der Holt, Okke de Weerdt, et al.
Blood Advances|February 22, 2021
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trialBob Löwenberg, Thomas Pabst, Johan Maertens, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Orphanet Journal of Rare Diseases|April 16, 2025
COVID- 19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNetPablo Velasco Puyo, Soteroula Christou, Saveria Campisi, et al.
Blood Advances|February 24, 2026
Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyureaSabine Haggenburg, Cilia R Pothast, Quincy Hofsink, et al.
Pageof 21

Showing results (201-210 of 209) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 209 results.
Blood Advances|October 31, 2025
Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Asparaginase-Treated ALLDaniela R Anderson, Radhika Gangaraju, Wafik G Sedhom, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2023
Clinical Impact of Polymerase Chain Reaction-Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter StudySammy Huygens, Albert Dunbar, Jochem B Buil, et al.
Vox Sanguinis|November 24, 2025
Multinational transfusion practices and outcomes in haematology patients admitted to the intensive care unitCaroline M Schaap, Laurens A Oomen, Senta Jorinde Raasveld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A studyMonique Terwijn, Wim L J van Putten, Angèle Kelder, et al.
Blood Advances|December 9, 2021
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trialAnita W Rijneveld, Bronno van der Holt, Okke de Weerdt, et al.
Blood Advances|February 22, 2021
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trialBob Löwenberg, Thomas Pabst, Johan Maertens, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Orphanet Journal of Rare Diseases|April 16, 2025
COVID- 19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNetPablo Velasco Puyo, Soteroula Christou, Saveria Campisi, et al.
Blood Advances|February 24, 2026
Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyureaSabine Haggenburg, Cilia R Pothast, Quincy Hofsink, et al.
Pageof 21